Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL27848258 | 0.94 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2762846 | 0.86 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL3675219 | 0.84 | KMT2A (0.52) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL3674393 | 0.83 | RAB9A (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL11057658 | 0.83 | MEN1 (0.63) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL5732752 | 0.81 | RAB9A (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL6793409 | 0.80 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL3682635 | 0.80 | LMNA (0.45) | MEN1KMT2AHSD11B1MGLL | |
| SCHEMBL2925097 | 0.80 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2763480 | 0.78 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099899-A1 | PROCESS FOR THE PURIFICATION OF 2-PHENYL-2-METHYL-PROPANOIC ACID DERIVATIVES | DIPHARMA FRANCIS S.R.L. (IT) | 2015-04-09 | — | — | US | claimed |
| CN-101585762-B | Method for synthesizing 2-(4-cyclopropoxycarbonylphenyl)-2-methylpropanoic acid | NINGBO INST TECH ZHEJIANG UNIV | 2012-12-19 | — | — | CN | claimed |
| CN-101585767-B | Method for synthesizing 2-[4-(4-chlorobutyryl)phenyl]-2-methacrylate | NINGBO INSTITUTE OF TECHNOLOGY, ZHEJIANG UNIVERSITY (CN) | 2012-02-15 | — | — | CN | claimed |
| CN-101585763-B | Method for synthesizing 2-[4-(4-chlorobutyryl)phenyl]-2-methylpropanoic acid | NINGBO INST TECH ZHEJIANG UNIV | 2012-01-04 | — | — | CN | claimed |
| CN-101585804-B | Synthetic method of a fexofenadine hydrochloride | NINGBO INST TECH ZHEJIANG UNIV | 2011-03-16 | — | — | CN | claimed |
| US-6903232-B2 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-α, α-dimethylphenylacetic acid | AUROBINDO PHARMA LTD. (IN) | 2005-06-07 | — | — | US | claimed |
| US-20040077900-A1 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid | AUROBINDO PHARMA LIMITED (IN) | 2004-04-22 | — | — | US | claimed |
| CN-116157811-A | Class dependent inference based on machine learning | 国际商业机器公司 | 2023-05-23 | — | — | CN | disclosed |
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
| EP-3365327-B1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2019-11-20 | — | — | EP | disclosed |
| CN-109071438-A | Process for the preparation of fexofenadine and intermediates used therein | 赛诺菲-安万特德国有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017068129-A1 | PROCESS FOR THE PREPARATION OF FEXOFENADINE AND OF INTERMEDIATES USED THEREIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2017-04-27 | — | — | WO | disclosed |
| US-9334223-B2 | Process for the purification of 2-phenyl-2-methyl-propanoic acid derivatives | DIPHARMA FRANCIS S.R.L. (IT) | 2016-05-10 | — | — | US | disclosed |
| CN-1128987-A | Novel intermediates for the preparation of antihistaminic piperidine derivatives | MERRELL DOW PHARMA (US) | 1996-08-14 | — | — | CN | disclosed |
| EP-0723958-A1 | Synthesis of substantially pure terfenadine derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 1996-07-31 | — | — | EP | disclosed |
| EP-0703902-A4 | — | ALBANY MOLECULAR RES INC (US) | 1996-04-10 | — | — | EP | disclosed |
| EP-0705245-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1996-04-10 | — | — | EP | disclosed |
| EP-0703902-A1 | PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | ALBANY MOLECULAR RESEARCH, INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995000480-A1 | NOVEL INTERMEDIATES FOR THE PREPARATION OF ANTIHISTAMINIC 4-DIPHENYLMETHYL/DIPHENYLMETHOXY PIPERIDINE DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| WO-1995000482-A1 | PIPERIDINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | ALBANY MOLECULAR RESEARCH, INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077900-A1 | Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-alpha, alpha-dimethylphenylacetic acid | CMA1, HRH1, HRH2 | MEN1 1657/4885KMT2A 1621/4885NPC1 2610/4885 |
| US-20150099899-A1 | PROCESS FOR THE PURIFICATION OF 2-PHENYL-2-METHYL-PROPANOIC ACID DERIVATIVES | PAH, NPFFR2, HRH2 | MEN1 2650/4885KMT2A 205/4885NPC1 4366/4885 |
| US-10696633-B2 | Process for the preparation of fexofenadine and of intermediates used therein | CYP4F2, CYP4F3, NISCH | MEN1 2626/4885KMT2A 2418/4885NPC1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.